H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) today and set a price target of $45.00. The company's shares closed last Friday at $5.75. According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -31.5% and a 13.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Applied Genetic Technologies, and Lineage Cell Therapeutics. Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $30.67, which is a 433.4% upside from current levels.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-gets-a-buy-rating-from-h-c-wainwright-3?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Déc 2022 à Jan 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2022 à Jan 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals